glp 1 drugs and blindness Lawsuits claiming Ozempic, other GLP-1s led to become second mass litigation over the GLP-1s and Eye Health: What

and the PEGylated agonist NLY01, which on this account does not effectively reach the brain despite being engineered for penetrance, was negative in a Phase 2 Parkinsons trial [12,13]

Raha, S

GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R

Posttranslational processing of preproglucagon The vast majority of glucagon is produced in the pancreatic -cells, but, under some conditions, small amounts of glucagon also have been detected in the intestinal L-cells [87], although the validity of immunoassays to distinguish different proglucagon products has been questioned, and some reports were unable to find genuine glucagon in the intestine by mass spectrometric analysis [[144], [145], [146]]

Therapy in the early stage: incretins